Author: healthprofessionalradio

David Elsley, MBA, President and CEO of Cardiol Therapeutics, Inc., a clinical stage biotech, discusses the Company’s research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). David talks about the Company’s lead product, CardiolRx™ a pharmaceutically produced oral cannabidiol formulation that has entered a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus who have a prior history of, or risk factors for, CVD. With the Delta variant spreading quickly, there is an urgent need to treat these high-risk patients. Cardiol is also planning to file an investigational new drug (“IND”) application for a Phase II international trial that will investigate the anti-inflammatory and anti-fibrotic properties of CardiolRx in patients with acute myocarditis, which remains the most common cause of sudden cardiac death in people under 35 years of age. 

​​Sheri Mullen, Senior Vice President, Specialty Business Unit, US Pharma at GSK discusses BENLYSTA (belimumab), the first and only biologic approved for lupus and lupus nephritis in adults, and its decade-in-market milestone. She shares insights around GSK leadership in reducing progression of long-term organ damage with BENLYSTA’s proven efficacy, investing in comprehensive lupus programs and clinical trials, revolutionizing the stagnant lupus landscape, and engaging lupus patient and advocacy communities to build trust and gain insights to better understand patient and caregiver needs and more.

​​Dr. Edio Zampaglione, Head of Global Medical Affairs and Outcomes Research at Organon and an OBGYN, discusses unintended pregnancies, the importance of starting conversations about birth control options with college-bound students, and a new study published in “Pediatrics” that shows that conversations with adolescents about sexual and reproductive health, other than puberty, aren’t routinely taking place during preventive care visits, even though 72% of 15-17-year-olds (and 78% of parents of 15-17-year-olds) consider discussions about methods of birth control important.

Returning guest, board-certified internist, Dr. Jacob Teitelbaum, MD, discusses the recently released (June 2021) 4th edition of his book “From Fatigued to Fantastic: A Clinically Proven Program to Regain Vibrant Health and Overcome Chronic Fatigue and Fibromyalgia” that now offers critical support for those with “long-hauler” syndrome following COVID-19 as well as new strategies for managing chronic fatigue and pain. 

Jim Joyce, co-founder, chairman, and CEO of Sigyn Therapeutics discusses the development of Sigyn Therapy, the company’s blood purification technology to overcome the limitations of drugs and other devices to treat Cytokine Storm induced inflammatory conditions that lead to sepsis. He explains the relationship between Cytokine Storm and COVID and how this blood purification technology is an approach that is getting alot of attention right now. He talks about how this technology differs from current blood purification technologies and what the current treatment landscape looks like. 

Sara Thomas, PhD, RD, registered dietician and research scientist at Abbott, discusses a new study from Abbott and The Ohio State University that was published in “Nutrients” that showed that adults with diabetes with low protein leads to physical limitations, lower overall diet quality, poorer nutrition density and more carbohydrates consumed. 

Rami Levin, President and CEO of Saniona discusses Tesomet, the first and only investigational treatment for Hypothalamic Obesity (HO) to receive orphan drug designation. This marks a major milestone for the patient community as there are currently no medications specifically approved for HO. Patients living with this disease experience uncontrollable hunger and intractable weight gain, which is often complicated by depression, impulse control issues and increased risk of cardiovascular and metabolic disorders. This milestone builds on the orphan drug designation granted by the FDA earlier this year to Tesomet for the treatment of Prader-Willi Syndrome (PWS) and Saniona is preparing to initiate Phase 2b studies of Tesomet in HO and PWS in the second half of this year.​ 

Dr. Bruce Bender, PhD, lead researcher and co-director of the Center for Health Promotion at National Jewish Health discusses recent research published in “The Journal of Allergy and Clinical Immunology: In Practice” about The Asthma Toolkit Bootcamp, a program that improved physician adherence to current guidelines, leading to fewer hospitalizations, emergency room visits, and decreased use of oral medications. 

Daniel Shapiro, author of “The Thin Ledge: A Husband’s Memoir of Love, Trauma, and Unexpected Circumstances” shares the reality of the fifteen years he spent living and caring for his wife, who suffered two massive brain hemorrhages and a personality change, while also single handedly raising their three young children. He discusses moving on and growing from trauma, moral issues, the struggle of a caregiver, and his perspective as a male caregiver. This book addresses questions that people living through unspeakable misfortunes may never mention, but almost always ask. ​​

Adam Sachs, co-founder and CEO of Vicarious Surgical, a company backed by Bill Gates and Vinod Khosla, discusses the company’s Fantastic Voyage inspired-surgical robot that uses immersive reality to guide today’s surgeons inside the body with new, groundbreaking technology that sets it apart from competitors. The system has received FDA Breakthrough Device designation.